This webinar will demonstrate how clinical laboratories can develop their own customized targeted next-generation sequencing (NGS)-based solid tumor panels.
Clinical labs that offer NGS-based tumor tests with different ranges of genes or mutations need to develop and validate customized assays that are accurate, sensitive, robust, affordable, easy to use, and free from cross-sample contamination.
Customization, however, can present significant obstacles for labs that lack the experience or financial resources required to design, develop, and validate the assay and interpret novel variants.
In this webinar, Dr. Paul Waring, Professor of Pathology at the University of Melbourne, will discuss how clinical labs can overcome these challenges. The webinar will provide details of Pillar Biosciences’ SLIMamp chemistry, ONCOReveal custom panel design, and Pillar Variant Analysis Toolkit, which provide clinical laboratories with the means to offer their own customized, affordable, single-tube tests suitable for detecting clinically relevant mutations in formalin-fixed tissue or blood samples with a sensitivity of at least 1%.
Key topics include:
- Applications of SLIMamp, a single-vial NGS chemistry to rapidly profile tumor samples
- Robust, sensitive mutation detection from samples with limited tumor input and liquid biopsies
- Bioinformatic workflows using the Pillar Variant Analysis Toolkit for rapid mutation identification
- Customization of the ONCOReveal assay to support clinical trials and identify emerging biomarkers
Due to our speaker being located in a different time zone, this webinar will be pre-recorded. All webinar registrants have the opportunity to submit questions on the registration page and/or you can email them in after the webinar is released on February 19th.